Septerna Inc Dossier
Qualitative Analysis
Business overview
Septerna, Inc. (NASDAQ: SEPN) is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery. Powered by its proprietary Native Complex Platform®, Septerna isolates, purifies, and reconstitutes GPCRs in their active signaling states to enable structure-based drug design, unlocking historically "undruggable" GPCR targets. The company's pipeline is focused on endocrinology, immunology and inflammation, and metabolic diseases.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing lead clinical candidates, including SEP-631 (MRGPRX2 antagonist for CSU) and SEP-479 (PTH1R agonist for hypoparathyroidism), through early and mid-stage clinical trials.
Expected impact: Establishing clinical proof-of-concept and validating the therapeutic potential of oral small molecules targeting historically challenging GPCRs.
Continued investment in and industrialization of the proprietary Native Complex Platform to rapidly generate differentiated oral small molecules for GPCR targets.
Expected impact: Unlocking historically undruggable GPCR targets and expanding the discovery pipeline across endocrinology, immunology, and metabolic diseases.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Collaborating to discover, develop, and commercialize oral small molecule medicines for obesity, type 2 diabetes, and other cardiometabolic diseases targeting specified GPCRs (including GLP-1, GIP, and glucagon receptors) [1.1.4].
Terms: Septerna received a $195.0 million upfront payment in July 2025 and is eligible to receive up to approximately $2.2 billion in total payments across upfront, research, development, and commercial milestones, plus tiered royalties on global net sales.
Vertex acquired an undisclosed discovery-stage GPCR program, with Vertex taking responsibility for continuing research and development.
Terms: Septerna received a $47.5 million upfront payment in September 2023, and is eligible for additional milestone payments (including a $12.5 million milestone received in 2025) and payments for the use of its Native Complex Platform.